Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

585.60 +6.26 (+1.08%)
Streaming Delayed Price Updated: 10:48 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,984
Open 580.21
Bid (Size) 585.02 (1)
Ask (Size) 586.65 (1)
Prev. Close 579.34
Today's Range 578.60 - 587.00
52wk Range 476.49 - 991.24
Shares Outstanding 91,779,465
Dividend Yield 0.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)
Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
-18.1%
-18.1%
1 Month
-1.7%
-1.7%
3 Month
+4.4%
+4.4%
6 Month
+0.0%
+0.0%
1 Year
-39.5%
-39.5%

More News

Read More
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.
Via Investor's Business Daily
Gapping S&P500 stocks in Monday's session
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today
Via Stocktwits
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
Via Benzinga
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
Via Stocktwits
Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors
Via Chartmill
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
Via Benzinga
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Stocks Down 17% and 21% to Buy Right Now
Via The Motley Fool
Topics World Trade
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Via Stocktwits
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss
Via Benzinga
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients
Via Benzinga
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Via Investor's Business Daily
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’
Via Stocktwits
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Via The Motley Fool
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
Wednesday's session: top gainers and losers in the S&P500 index
Via Chartmill

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 585.60
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 10/22/25 10:48 AM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 53.75B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 54B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.